Assessing congenital malformation risk from medications used in pregnancy: The contribution of NBDPS in pregnancy labeling of prescription drug products

ConclusionThe Pregnancy and Lactation Labeling Rule will set new and improved standards for the inclusion of information about the use of prescription drugs and biological products during pregnancy; the National Birth Defects Prevention Study, along with other data sources, will be critical for providing safety data to inform product labeling. Birth Defects Research (Part A), 2015. © 2015 Wiley Periodicals, Inc.

Source: Birth Defects Research Part A: Clinical and Molecular Teratology - July 1, 2015 Category: Perinatology & Neonatology Authors: Melissa S. Tassinari, Leyla Sahin, Lynne P. Yao Tags: Brief Report Source Type: research